The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
789
Tablet, Oral, 0.0 mg, Once daily, 54 weeks
Tablet, Oral, 0.5 mg, Once daily, 54 weeks
Tablet, Oral, 1.0 mg, Once daily, 54 weeks
Long-term effects of BMS-820836 on blood pressure in patients with depression
Time frame: Baseline through Week 54
• Adverse Events (AEs), Serious Adverse Events, and Discontinuations Due to AEs
Time frame: Baseline through Week 54
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tablet, Oral, 2.0 mg, Once daily, 54 weeks
Birmingham Psychiatry Pharmaceutical Studies, Inc.
Birmingham, Alabama, United States
K & S Professional Research Services, Llc
Little Rock, Arkansas, United States
Arkansas Psychiatric Clinic Clinical Research Trials, P.A.
Little Rock, Arkansas, United States
Pacific Clinical Research Medical Group
Arcadia, California, United States
Catalina Research Institute, Llc
Chino, California, United States
Pharmacology Research Institute
Encino, California, United States
Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States
Behavioral Research Specialists, Llc
Glendale, California, United States
Pharmacology Research Institute
Los Alamitos, California, United States
Pharmacology Research Institute
Newport Beach, California, United States
...and 134 more locations